Endovastec(688016)2024-11-04 08:54Financial Performance - The company's revenue for the first three quarters of 2024 reached 970 million CNY, representing a year-on-year growth of 9.13% [1][2] - Net profit attributable to shareholders was 553 million CNY, showing a significant increase of 42.46% year-on-year [2] - Basic earnings per share stood at 4.49 CNY, reflecting a growth of 24.03% compared to the previous year [2] Market Presence - The company's products have been adopted in over 2,400 domestic hospitals [2] - The Castor branched aortic stent and delivery system has covered more than 1,100 terminal hospitals [2] - The Minos abdominal aortic stent and delivery system has reached over 900 terminal hospitals [2] - The Reewarm PTX drug-coated balloon catheter has been implemented in over 1,100 terminal hospitals [2] - New products like the Fontus branched intraoperative stent system and Talos straight thoracic aortic stent system have entered over 200 and 300 hospitals, respectively [2] Global Expansion - The company has obtained over 60 overseas registrations, with products entering clinical applications in 40 countries including Europe, Latin America, and Southeast Asia [2] - The full acquisition of Optimum Medical Device Inc. has enhanced the company's presence in the European market [2] Product Features - The Veryan BM3D® peripheral stent system is noted for being the world's first and only spiral-structured peripheral vascular stent, designed to reduce the risk of stent fracture [3] - The polyethylene glycol embolization microspheres have been submitted for registration, with features aimed at precise tumor vascular treatment [3][4] Integration Progress - The integration with Lombard is progressing smoothly, as both companies have collaborated for many years [4]